Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in …
June 7, 2011 by
Filed under class registration system
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in …
EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ — Novartis Pharmaceuticals Corporation (“Novartis”) will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology [...]
Teva and CureTech Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell …
May 23, 2011 by
Filed under class registration system
Teva and CureTech Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell …
JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody. CT-011 met the primary endpoint of improved [...]
Positive data from Gloucester Pharmaceuticals’ ISTODAX study presented at the ASH meeting
December 6, 2009 by
Filed under class registration software
Positive data from Gloucester Pharmaceuticals’ ISTODAX study presented at the ASH meeting
Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, [...]